Daclatasvir + sofosbuvir demonstrates good cure rate for genotype 3 hepatitis C
Positive response to 'gift tokens for undetectable viral load' trial
AbbVie 3D regimen and sofosbuvir/ribavirin show high cure rates for HCV in people with HIV co-infection
Sofosbuvir + GS-5816 for 12 weeks shows high HCV cure rates, but 8 weeks is less effective for some patients
HIV in the UK: 76% diagnosed, 90% on treatment, 90% undetectable
Adding pegylated interferon to tenofovir improves odds of HBsAg loss in hepatitis B patients
Gay men in UK recommended to receive HPV vaccination
Merck's grazoprevir/elbasvir combo shows high cure rates, including for people with cirrhosis and HIV/HCV co-infection
Sofosbuvir/ledipasvir and AbbVie 2D regimen cure most people with HCV genotype 4
